Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.

Epilepsy research - 1 Jan 2009

Lynch J M, Tate S K, Kinirons P, Weale M E, Cavalleri G L, Depondt C, Murphy K, O'Rourke D, Doherty C P, Shianna K V, Wood N W, Sander J W, Delanty N, Goldstein D B, Sisodiya S M

Abstract excerpt

Levetiracetam (LEV), a newer antiepileptic drug (AED) useful for several epilepsy syndromes, binds to SV2A. Identifying genetic variants that influence response to LEV may allow more tailored use of LEV. Obvious candidate genes are SV2A, SV2B and SV2C, which encode the only known binding site, synaptic vesicle protein 2 (SV2), with LEV binding to the SV2A isoform. SV2A is an essential protein as homozygous SV2A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Epilepsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epilepsy, Temporal Lobe

Share to Hippocampus

Share to Ireland

Share to Membrane Glycoproteins

Share to Synaptic Vesicles

Share to United Kingdom

Source

Identifiers

PMID: 18977120
DOI: 10.1016/j.eplepsyres.2008.09.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.PMID 18977120Read ↗

Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.Semantic proximity Read ↗

Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants.Semantic proximity Read ↗

Testing association of rare genetic variants with resistance to three common antiseizure medications.Semantic proximity Read ↗

Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.Semantic proximity Read ↗

Whole genome sequencing identifies putative associations between genomic polymorphisms and clinical response to the antiepileptic drug <i>levetiracetam</i>Semantic proximity Read ↗

Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.Semantic proximity Read ↗

Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.Semantic proximity Read ↗

Efficacy of levetiracetam in STXBP1 encephalopathy with different phenotypic and genetic spectra.Semantic proximity Read ↗

Genetic polymorphism of drug refractory epilepsy.Semantic proximity Read ↗

Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.Semantic proximity Read ↗

Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam.Semantic proximity Read ↗

Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.